HMGB1 and neoplasm: The interaction between HMGB1 and TLR4 can mediate signal transduction of the inflammatory response via MYD88, which activates the NF-κB signaling pathway, leading to the release of inflammatory factors, and ultimately triggering tumor antigen-specific T-cell immunity [20].